SLRX Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc. a clinical-stage oncology company, develops therapies for the treatment of patients with various cancers. The company's lead candidate is Seclidemstat, which is in clinical development for the treatment of Ewing sarcoma, as well as advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.

$1.87
As of 03/02/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
01/29/2015
23,808,546
6,057,366
$46,902,836
0.00%
SEC Edgar Online
10-Q
10-K
79400X107
US79400X1072
BK0YL86

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-6.28
1.89
9.79
-36.24%
-155.80%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy